2. Academic Validation
  3. Targeting Neuronal GPR65 With Delayed BTB09089 Treatment Improves Neurorehabilitation Following Ischemic Stroke

Targeting Neuronal GPR65 With Delayed BTB09089 Treatment Improves Neurorehabilitation Following Ischemic Stroke

  • Stroke. 2024 Aug;55(8):2151-2162. doi: 10.1161/STROKEAHA.124.046954.
Ru Chen # 1 2 3 4,  Meng-Qi Zhang # 1 2 3 4,  Yu-Lu Miao # 1 2 3 4,  Shu-Han Zhang 1 2 3 4,  Yao Cheng 1 2 3 4,  Shao-Shuai Wang 1 2 3 4,  Jing Yin 1 2 3 4,  Cai-Hong Yang 1 2 3 4,  Hui-Feng Zhang 1 2 3 4,  Li Tang 1 2 3 4,  Yan Li 1 2 3 4,  Yu Zhang 1 2 3 4,  Yan-Ying Fan 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Pharmacology, School of Basic Medical Science (R.C., M.-Q.Z., Y.-L.M., S.-H.Z., Y.C., J.Y., C.-H.Y., H.-H.Z., Y.L., Y.-Y.F.), Shanxi Medical University, Jinzhong, China.
  • 2 Medicinal Basic Research Innovation Centre of Chronic Kidney Disease, Ministry of Education (Y.C., L.T., Y.-Y.F.), Shanxi Medical University, Jinzhong, China.
  • 3 Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, China (Y.-L.M., C.-H.Y., H.-F.Z., Y.L., Y.Z.).
  • 4 Department of Neurology, First Hospital of Shanxi Medical University, Taiyuan, China (S.-S.W.).
  • # Contributed equally.
PMID: 38946544 DOI: 10.1161/STROKEAHA.124.046954
Abstract

Background: GPR65 (G protein-coupled receptor 65) can sense extracellular acidic environment to regulate pathophysiological processes. Pretreatment with the GPR65 agonist BTB09089 has been proven to produce neuroprotection in acute ischemic stroke. However, whether delayed BTB09089 treatment and neuronal GPR65 activation promote neurorestoration remains unknown.

Methods: Ischemic stroke was induced in wild-type (WT) or GPR65 knockout (GPR65-/-) mice by photothrombotic ischemia. Male mice were injected intraperitoneally with BTB09089 every other day at days 3, 7, or 14 poststroke. AAV-Syn-GPR65 (adenoassociated virus-synapsin-GPR65) was utilized to overexpress GPR65 in the peri-infarct cortical neurons of GPR65-/- and WT mice. Motor function was monitored by grid-walk and cylinder tests. The neurorestorative effects of BTB09089 were observed by immunohistochemistry, Golgi-Cox staining, and Western blotting.

Results: BTB09089 significantly promoted motor outcomes in WT but not in GPR65-/- mice, even when BTB09089 was delayed for 3 to 7 days. BTB09089 inhibited the activation of microglia and glial scar progression in WT but not in GPR65-/- mice. Meanwhile, BTB09089 reduced the decrease in neuronal density in WT mice, but this benefit was abolished in GPR65-/- mice and reemerged by overexpressing GPR65 in peri-infarct cortical neurons. Furthermore, BTB09089 increased the GAP43 (growth-associated protein-43) and synaptophysin puncta density, dendritic spine density, dendritic branch length, and dendritic complexity by overexpressing GPR65 in the peri-infarct cortical neurons of GPR65-/- mice, which was accompanied by increased levels of p-CREB (phosphorylated cAMP-responsive element-binding protein). In addition, the therapeutic window of BTB09089 was extended to day 14 by overexpressing GPR65 in the peri-infarct cortical neurons of WT mice.

Conclusions: Our findings indicated that delayed BTB09089 treatment improved neurological functional recovery and brain tissue repair poststroke through activating neuronal GRP65. GPR65 overexpression may be a potential strategy to expand the therapeutic time window of GPR65 agonists for neurorehabilitation after ischemic stroke.

Keywords

ischemic stroke; mice; neurological rehabilitation; neuronal plasticity; receptors, G-protein-coupled.

Figures
Products